ArticleJournal of gastroenterology2025

Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.

Tomoko Aoki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.